Every promising drug therapy has a potential dark side. Hycamtin -- topotecan hydrochloride -- a cancer-fighting drug used to treat patients with ovarian and lung cancer, has received FDA approval for treatment of late-stage cervical cancer. When surgery or radiation is not a viable option for women diagnosed with recurrent or incurable cervical cancer, Hycamtin can be added to cisplatin as a combination chemotherapy drug therapy shown to provide life-lengthening benefit.

Combining Hycamtin with cisplatin is not a cure, and in clinical trials showed an additional survival benefit of three months when compared to treatment with cisplatin alone. Who would not choose to live as long as possible, even if you are measuring life in months? However, the combination drug therapy is likely to increase the risk in lowering white cell counts, decreasing blood platelets, inducing nausea, vomiting, diarrhea and hair loss. Quantity of life versus quality of life is the dark side of this drug therapy promise. One woman might choose quantity of life, and another woman choose quality of life. There is no wrong or right but when making a choice it needs to be made with eyes wide open.

For more information, there is a Hycamtin website offering information on how the chemotherapy drug is administered and the side effects a woman can expect during treatment. While it is written for ovarian and lung cancer patients, I believe the basic over all information should be the same for cervical cancer patients.

Thanks to Joel Arellano of Autoblog for this news tip!